This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Impax Laboratories Reports Third Quarter 2012 Results

The following table reconciles reported net income to adjusted net income.

      Three months ended       Nine months ended

(Unaudited, amounts in millions, except per share data)

September 30, September 30,
2012     2011 2012     2011
Net income $ 20.0 $ 17.2 $ 51.1 $ 43.6
Adjusted to add (deduct):
Amortization and acquisition-related costs (a) 22.1 - 36.4 -
Generic product withdrawal costs (b) 2.0 - 2.0 -
Patent litigation settlement reimbursement (c) (5.0 ) - (5.0 ) -
Gross profit earned on Zomig® Agreement - - 46.2 -
Acquisition related in process R&D - - 1.6 -
Employee severance - - 1.9 0.8
Inventory adjustment - - 3.5 -
Lower of cost or market charge - - 1.7 -
Income tax effect   (6.6 )   -   (30.4 )   (0.3 )
Adjusted net income $ 32.5   $ 17.2 $ 109.0   $ 44.1  
 
Net income adjusted per diluted share $ 0.48 $ 0.26 $ 1.60 $ 0.66
Net income per diluted share $ 0.29 $ 0.26 $ 0.75 $ 0.65
 
 

Impax Laboratories, Inc.

Non-GAAP Financial Measures
 

The following table reconciles reported net income to adjusted EBITDA.

      Three months ended       Nine months ended

(Unaudited, amounts in millions)

September 30, September 30,
2012     2011 2012     2011
Net income $ 20.0 $ 17.2 $ 51.1 $ 43.6
Adjusted to add (deduct):
Interest income (0.3 ) (0.3 ) (0.8 ) (0.9 )
Interest expense 0.1 0.1 0.6 0.1
Depreciation and other 4.3 3.5 11.9 11.9
Income taxes   9.6     8.5     27.2     20.8  
EBITDA   33.7     29.0     90.0     75.5  
 
Adjusted to add:
Amortization and acquisition-related costs (a) 22.1 - 36.4 -
Generic product withdrawal costs (b) 2.0 - 2.0 -
Patent litigation settlement reimbursement (c) (5.0 ) - (5.0 ) -
Gross profit earned on Zomig® Agreement - - 46.2 -
Acquisition related in process R&D - - 1.6 -
Employee severance - - 1.9 0.8
Inventory adjustment - - 3.5 -
Lower of cost or market charge - - 1.7 -
Share-based compensation   3.8     3.5     12.1     9.6  
Adjusted EBITDA $ 56.6   $ 32.5   $ 190.4   $ 85.9  
 
(a)     Amortization and acquisition-related costs from the January 2012 Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited and the June 2012 Development, Distribution and Supply Agreement with TOLMAR, Inc.
 
(b) The Company recorded a charge of $2.0 million related to the voluntary withdrawal from the market of bupropion XL 300 mg, manufactured by Impax and marketed through our Strategic Alliance Agreement with Teva.
 
(c) The Company received $5.0 million for reimbursement of legal fees pursuant to the settlement of litigation.
 




6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,006.47 -63.93 -0.35%
S&P 500 2,101.24 -13.25 -0.63%
NASDAQ 4,959.8320 -57.0970 -1.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs